Published in Clin Liver Dis on August 01, 2007
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 2.49
Statin therapy and serum transaminases among a cohort of HCV-infected veterans. Dig Dis Sci (2010) 1.57
Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One (2012) 1.10
Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc (2010) 1.06
Nicotinamide overload may play a role in the development of type 2 diabetes. World J Gastroenterol (2009) 1.03
Treating statin-intolerant patients. Diabetes Metab Syndr Obes (2011) 1.01
Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci (2012) 0.96
Bioenergetic study of murine hepatic tissue treated in vitro with atorvastatin. BMC Pharmacol Toxicol (2013) 0.92
Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology (2016) 0.86
Serious drug-induced liver disease secondary to ezetimibe. World J Gastroenterol (2008) 0.85
Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease? World J Gastroenterol (2010) 0.85
HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nat Rev Nephrol (2015) 0.82
Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. Int J Clin Pharmacol Ther (2010) 0.82
Statin associated hepatic adverse effects: a retrospective review from a regional hospital in sultanate of oman. Oman Med J (2014) 0.80
Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis. Best Pract Res Clin Endocrinol Metab (2013) 0.78
Statins and its hepatic effects: Newer data, implications, and changing recommendations. J Pharm Bioallied Sci (2016) 0.76
Statin-induced myopathy in a usual care setting-a prospective observational study of gender differences. Eur J Clin Pharmacol (2016) 0.75
Hepatotoxicity Associated with a Short Course of Rosuvastatin. Chin Med J (Engl) (2015) 0.75
Withholding statins in patients with underlying liver disease: wise or unwise? Proc (Bayl Univ Med Cent) (2010) 0.75
Acute hepatic injury with atorvastatin: an unusual occurrence. Indian J Pharmacol (2014) 0.75
The reduction of serum aminotransferase levels is proportional to the decline of the glomerular filtration rate in patients with chronic kidney disease. Clinics (Sao Paulo) (2015) 0.75
Effect of Morinda citrifolia (Noni) Fruit Juice on High Fat Diet Induced Dyslipidemia in Rats. J Clin Diagn Res (2016) 0.75
10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. BMJ Open (2017) 0.75
Carcinogenicity of lipid-lowering drugs. JAMA (1996) 7.04
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol (2004) 6.50
A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA (1994) 4.38
Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet (2004) 3.59
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation (2002) 3.29
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology (2004) 3.27
Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation (2005) 2.49
The liver and lovastatin. Am J Cardiol (2002) 2.49
Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 2.11
Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl (2004) 1.96
An assessment of statin safety by hepatologists. Am J Cardiol (2006) 1.78
Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med (1989) 1.74
Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab Rev (2004) 1.64
Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet (1999) 1.59
Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology (2006) 1.56
Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol (2006) 1.55
Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin Proc (1991) 1.54
Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation (2002) 1.51
Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol (2003) 1.49
Fatal liver failure with atorvastatin. J Hepatol (2003) 1.49
Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med (1994) 1.45
Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology (2005) 1.45
ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias. American Society of Health-System Pharmacists. Am J Health Syst Pharm (1997) 1.45
Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf (2000) 1.42
Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis (2002) 1.32
Severe hepatic side effects of ezetimibe. Clin Gastroenterol Hepatol (2006) 1.31
Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol (1998) 1.28
Statins and liver toxicity: a meta-analysis. Pharmacotherapy (2004) 1.13
Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci (2005) 1.07
Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem Pharmacol (2004) 1.05
High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol (2004) 1.03
Preclinical evaluation of lovastatin. Am J Cardiol (1988) 1.03
Risk of adverse events with fibrates. Am J Cardiol (2004) 1.03
Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. JAMA (1990) 1.01
Safety issues with statin therapy. J Am Pharm Assoc (2003) (2006) 1.01
Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol (1997) 1.00
Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem (2005) 1.00
Acute hepatic failure associated with the use of low-dose sustained-release niacin. JAMA (1990) 0.98
Nicotinic acid-induced fulminant hepatic failure. J Clin Gastroenterol (1987) 0.96
Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med (1992) 0.94
Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann Pharmacother (2006) 0.94
Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis (2003) 0.93
Defining patient risks from expanded preventive therapies. Am J Cardiol (2000) 0.92
Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol (2006) 0.92
Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr Med Res Opin (2006) 0.91
Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves. Arch Intern Med (1999) 0.89
Hepatotoxicity associated with sustained-release niacin. Am J Med (1992) 0.88
Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver. Hepatology (2006) 0.88
Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs (2005) 0.87
Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor). Pharmacol Toxicol (1990) 0.86
Safety of statins when response is carefully monitored: a study of 336 heart recipients. Transplant Proc (2005) 0.85
[Acute cholestatic hepatitis after atorvastatin reintroduction]. Gastroenterol Hepatol (2006) 0.85
Statins for hyperlipidemia in patients with chronic liver disease: are they safe? Clin Gastroenterol Hepatol (2006) 0.85
Fenofibrate-induced acute cholestatic hepatitis. J Chin Med Assoc (2004) 0.85
Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med (2001) 0.85
Niacin extended-release/lovastatin: combination therapy for lipid disorders. Expert Opin Pharmacother (2002) 0.85
Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Dig Dis Sci (1994) 0.84
Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am J Health Syst Pharm (2003) 0.84
Profiling of hepatic gene expression in rats treated with fibric acid analogs. Mutat Res (2004) 0.84
Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature. Pharmacotherapy (2004) 0.83
Niacin for dyslipidemia: considerations in product selection. Am J Health Syst Pharm (2003) 0.82
Acute cholestatic hepatitis associated with pravastatin. Am J Gastroenterol (1999) 0.81
Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus (2003) 0.81
Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol (2005) 0.79
Safety and efficacy of atorvastatin in heart transplant recipients. J Heart Lung Transplant (2002) 0.79
Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Dig Dis Sci (2001) 0.79
Comparative metabolism and disposition of gemfibrozil in male and female Sprague-Dawley rats and Syrian golden hamsters. Drug Metab Dispos (1999) 0.79
Transient focal hepatic defects related to sustained-release niacin. J Clin Gastroenterol (1993) 0.79
Statins and cancer: a case of meta-uncertainty. Am J Med (2001) 0.78
Safety and side effects of sustained-release niacin. JAMA (1994) 0.78
Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int J Clin Pract (2005) 0.78
Effect of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on hepatic cell proliferation and toxicity in Sprague-Dawley rats. Carcinogenesis (1994) 0.78
[Cholestatic hepatitis caused by gemfibrozil]. Rev Esp Enferm Dig (2001) 0.77
Colesevelam hydrochloride in the management of dyslipidemia. Expert Rev Cardiovasc Ther (2006) 0.77
Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy. Med Oncol (2006) 0.77
Flutamide-induced hepatotoxicity with possible potentiation by simvastatin. J Assoc Physicians India (2003) 0.77
The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe. Curr Med Res Opin (2005) 0.77
[Mechanisms of hepatotoxicity]. Arq Bras Cardiol (2006) 0.77
Niacin-induced hepatitis and thrombocytopenia after 10 years of niacin use. J Clin Gastroenterol (1994) 0.76
Colestipol-induced hepatotoxicity. Pharmacotherapy (2001) 0.76
Ultrasonographic findings in niacin-induced hepatitis. J Ultrasound Med (1999) 0.76
Effects of niacin therapy that simulate neoplasia: hepatic steatosis with concurrent hepatic dysfunction. J Comput Assist Tomogr (1999) 0.76
Niacin-induced hepatotoxicity: unusual presentations. South Med J (1994) 0.76
[Acute hepatitis caused by gemfibrozil]. Gastroenterol Hepatol (1998) 0.76
Ezetimibe/Simvastatin (vytorin) for hypercholesterolemia. Am Fam Physician (2005) 0.76
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology (2008) 2.66
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Initial experience with EUS-guided Tru-cut biopsy of benign liver disease. Gastrointest Endosc (2009) 2.30
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Endoscopic therapy with 2-octyl-cyanoacrylate for the treatment of gastric varices. Dig Dis Sci (2014) 1.99
Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology (2010) 1.91
An assessment of statin safety by hepatologists. Am J Cardiol (2006) 1.78
Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology (2009) 1.78
Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci (2005) 1.76
Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int (2005) 1.71
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology (2008) 1.70
Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. Gastrointest Endosc (2002) 1.70
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study. Hepatology (2009) 1.59
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology (2010) 1.58
Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci (2011) 1.52
Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol (2004) 1.48
Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol (2010) 1.48
Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2015) 1.46
Langerhans' cell histiocytosis involving the pituitary, thyroid, lung, and liver. Endocr Pract (2002) 1.45
Relationship between unexplained elevations in alanine aminotransferase and serum leptin in U.S. adults: results from the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Gastroenterol (2004) 1.43
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci (2013) 1.40
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol (2011) 1.38
The impact of videorecording on the quality of colonoscopy performance: a pilot study. Am J Gastroenterol (2010) 1.28
Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol (2007) 1.24
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study. Am J Gastroenterol (2010) 1.19
Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples. J Clin Gastroenterol (2007) 1.18
Validation of a multivariate model predicting presence and size of varices. J Clin Gastroenterol (2007) 1.15
Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol (2003) 1.14
A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology (2011) 1.12
Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr (2011) 1.12
Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol (2010) 1.10
Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci (2008) 1.10
Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis (2009) 1.10
Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis (2004) 1.09
NAFLD fibrosis score: is it ready for wider use in clinical practice and for clinical trials? Gastroenterology (2013) 1.08
Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol (2008) 1.08
Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci (2005) 1.07
Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis (2012) 1.06
Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. Hepatology (2002) 1.05
Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep (2008) 1.03
Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol (2011) 1.02
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int (2014) 1.02
Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology (2002) 1.02
Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther (2005) 0.99
Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol (2007) 0.99
CD59 incorporation protects hepatitis C virus against complement-mediated destruction. Hepatology (2011) 0.98
Vitamin d deficiency in patients with chronic liver disease and cirrhosis. Curr Gastroenterol Rep (2012) 0.96
Nurse-administered propofol versus midazolam and meperidine for upper endoscopy in cirrhotic patients. Am J Gastroenterol (2003) 0.94
Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sci (2003) 0.94
Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients. AJR Am J Roentgenol (2013) 0.94
Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol (2010) 0.93
Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep (2009) 0.93
De novo malignancy post-liver transplantation: a single center, population controlled study. Clin Transplant (2013) 0.91
Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg (2010) 0.91
Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol (2010) 0.90
Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg (2013) 0.90
What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol (2012) 0.89
Idiosyncratic drug-induced liver injury: a clinical update. Curr Gastroenterol Rep (2011) 0.89
Nonalcoholic fatty liver disease (NAFLD): is it really a serious condition? Hepatology (2012) 0.88
Factors that predict short-term intensive care unit mortality in patients with cirrhosis. Clin Gastroenterol Hepatol (2013) 0.88
Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol (2005) 0.88
Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics. Hepatology (2005) 0.87
Drug-induced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience. J Clin Gastroenterol (2013) 0.85
Management of hepatitis C infection after liver transplantation. Drugs (2007) 0.85
Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl (2004) 0.85
Statins for hyperlipidemia in patients with chronic liver disease: are they safe? Clin Gastroenterol Hepatol (2006) 0.85
Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Am J Physiol Gastrointest Liver Physiol (2010) 0.85
Nonalcoholic fatty liver disease liver fat score and fat equation to predict and quantitate hepatic steatosis: promising but not prime time! Gastroenterology (2009) 0.85
Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis. PLoS One (2013) 0.84
Acute cholecystitis after colonoscopy: a case series. Gastrointest Endosc (2011) 0.84
Impact of the Interaction between 3'-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes. Front Genet (2012) 0.84
Portal Vein Thrombosis Is a Risk Factor for Poor Early Outcomes After Liver Transplantation: Analysis of Risk Factors and Outcomes for Portal Vein Thrombosis in Waitlisted Patients. Transplantation (2016) 0.84
Oxidative stress in chronic liver disease: relationship between peripheral and hepatic measurements. Am J Med Sci (2011) 0.84
Noninvasive markers of advanced histology in nonalcoholic fatty liver disease: are we there yet? Gastroenterology (2007) 0.84
Cost-effectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding. Hepatology (2007) 0.83
Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol (2005) 0.83
Fatty acid desaturase 1 gene polymorphisms control human hepatic lipid composition. Hepatology (2014) 0.83
Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. Eur J Clin Pharmacol (2012) 0.82
Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis. Liver Int (2014) 0.82
Serum hepcidin levels are associated with obesity but not liver disease. Obesity (Silver Spring) (2013) 0.81
Drug-induced liver injury in clinical trials: as rare as hens' teeth. Am J Gastroenterol (2009) 0.81
Hepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes. J Clin Gastroenterol (2011) 0.81
The confusion assessment method for the intensive care unit in patients with cirrhosis. Metab Brain Dis (2015) 0.81
Effect of different obesogenic diets on pancreatic histology in Ossabaw miniature swine. Pancreas (2011) 0.80
Utility of formalin-fixed, paraffin-embedded liver biopsy specimens for global proteomic analysis in nonalcoholic steatohepatitis. Proteomics Clin Appl (2011) 0.80
Prevalence and morbidity associated with muscle cramps in patients with cirrhosis. Am J Med (2012) 0.80
Bleeding caused by portal hypertension. Gastroenterol Clin North Am (2005) 0.80
Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events. Hepatology (2014) 0.79
Restoration of bile ducts in drug-induced vanishing bile duct syndrome due to zonisamide. Am J Surg Pathol (2006) 0.79